On Monday, January 14, the U.S. Supreme Court denied a petition for writ of certiorari by Apotex Inc. challenging a May 2012 Federal Circuit ruling in favor of Otsuka Pharmaceutical Co., Ltd. The petition concerned the Federal Circuit’s so-called lead compound test for evaluating the obviousness of drug patents. This test was applied to uphold the validity of Otsuka’s antipsychotic drug Abilify®. Otsuka was represented by Finnegan in this matter. Finnegan partner James Monroe was pleased the Supreme Court did not take up the Apotex appeal and said, “We're very happy that the court denied the petition.”
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.